Physician profile
Scott A Young
NPI 1104018977
$23,892.24
in general payments reported to CMS, 2019-2025
59 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,001 · 2020: $3,627 · 2021: $5,213 · 2022: $4,591 · 2023: $3,472 · 2024: $2,530 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,459.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,602.40 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $1,976.72 | 2019-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $1,481.29 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,457.32 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $1,363.80 | 2019-2024 | Vraylar, Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $1,354.04 | 2019-2022 | |
| Esperion Therapeutics, INC. | $1,329.11 | 2020-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $1,186.93 | 2019-2025 | Entresto, Leqvio |
| Novo Nordisk INC | $1,176.56 | 2019-2023 | |
| Pfizer INC. | $768.28 | 2019-2023 | |
| Lilly USA, LLC | $735.49 | 2019-2023 | Mounjaro, Jardiance |
| Amarin Pharma, INC. | $685.07 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $616.21 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $575.34 | 2019-2025 | Trintellix |
| Bausch Health US, LLC | $522.54 | 2019-2022 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.